Latest news with #RobbinsLLP
Associated Press
a day ago
- Business
- Associated Press
HIMS Investor Notice: Robbins LLP Reminds Hims & Hers Health, Inc. Stockholders of the Class Action Against the Company
SAN DIEGO, CA - June 28, 2025 ( NEWMEDIAWIRE ) - Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Hims & Hers Health, Inc. (NYSE: HIMS) securities between April 29, 2025 and June 22, 2025. Hims operates a telehealth platform that connects consumers to licensed healthcare professionals. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Allegations that Hims & Hers Health, Inc. (HIMS) Deceptively Promoted and Sold Illegitimate Versions of Wegovy(R) According to the complaint, on April 29, 2025, Hims announced a long-term collaboration with Novo Nordisk, starting with the immediate sale of 'a bundled offering of Novo Nordisk's FDA-approved Wegovy(R) on the Hims & Hers platform.' However, on June 23, 2025, Novo Nordisk issued a press release announcing that it was terminating its partnership with Hims, 'based on Hims & Hers deceptive promotion and selling of illegitimate, knockoff versions of Wegovy(R) that put patient safety at risk.' On this news, the Company's share price fell $22.24, or 34.6%, to close at $41.98 per share on June 23, 2025. Plaintiff alleges that during the class period, defendants failed to disclose to investors: (1) that Hims was engaged in the 'deceptive promotion and selling of illegitimate, knockoff versions of Wegovy(R) that put patient safety at risk;' and (2) that, as a result, there was a substantial risk that the Company's collaboration with Novo Nordisk would be terminated. What Now: You may be eligible to participate in the class action against Hims & Hers Health, Inc. Shareholders who want to serve as lead plaintiff for the class must file a motion for lead plaintiff by August 25, 2025. The lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here. All representation is on a contingency fee basis. Shareholders pay no fees or expenses. About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against Hims & Hers Health, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today. Attorney Advertising. Past results do not guarantee a similar outcome. Contact: Aaron Dumas, Jr. Robbins LLP 5060 Shoreham Pl., Ste. 300 San Diego, CA 92122 [email protected] (800) 350-6003
Associated Press
3 days ago
- Business
- Associated Press
KNBE Stock News: Former KnowBe4 (KNBE) Stockholders Should Contact Robbins LLP for Information Regarding the Securities Fraud Class Action on Their Behalf
SAN DIEGO, June 27, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of investors (i) who held KnowBe4, Inc. (NASDAQ: KNBE) common stock as of the December 7, 2022, record date that were entitled to vote on the 'take private' acquisition ('Merger') by Vista Equity Partners Management LLC and its affiliates, or (ii) sold shares of KnowBe4 common stock from the October 12, 2022, announcement date through the February 1, 2023, close of the Merger. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Allegations that KnowBe4, Inc. (KNBE) Misled Investors Regarding its Acquisition by Vista Equity Partners Management LLC According to the complaint, defendants issued or caused to be issued SEC filings that contained numerous false or misleading statements or omitted material facts concerning: (i) the unfair sales process that provided distinct advantages to Vista; (ii) the Special Committee's purported independence; (iii) KKR's intention to increase its rollover or reinvestment into the post-close KnowBe4 by 50-100% after learning the deal price; (iv) the Special Committee's favoritism towards Vista over other potential bidders; (v) the Special Committee's failure to consider strategic alternatives other than a sale of KnowBe4; and (vi) the Company's largest non-Rollover Stockholder, Mitnick, owed his personal fortune and professional legitimacy to Sjouwerman, and therefore was not independent from members of the Control Group. These filings contained materially false and misleading statements and omissions, thereby denying stockholders an appropriately informed vote on the Merger and an appropriately informed opportunity to decide whether to accept the Merger consideration or instead exercise their appraisal rights. What Now: You may be eligible to participate in the class action against KnowBe4, Inc. Shareholders who want to serve as lead plaintiff for the class must file a motion for lead plaintiff by August 5, 2025. The lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here. All representation is on a contingency fee basis. Shareholders pay no fees or expenses. About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against KnowBe4, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today. Attorney Advertising. Past results do not guarantee a similar outcome.
Associated Press
3 days ago
- Business
- Associated Press
TEM Investors with Large Losses Should Contact Robbins LLP for Information About Leading the Securities Fraud Class Action Against TEM
SAN DIEGO, June 27, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Tempus AI, Inc. (NASDAQ: TEM) common stock between August 6, 2024 and May 27, 2025. Tempus purports to be provide Artificial Intelligence ('AI') enabled precision medicine solutions. For more information, submit a form , email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Allegations that Tempus AI, Inc. (TEM) Misled Investors Regarding its Business Prospects According to the complaint, defendants failed to disclose: (1) Tempus inflated the value of contract agreements, many of which were with related parties, included non-binding opt-ins and/or were self-funded; (2) the credibility and substance of the joint venture with SoftBank was at risk because it gave the appearance of 'round-tripping' capital to create revenue for Tempus; (3) Tempus-acquired Ambry had a business model based on aggressive and potentially unethical billing practices that risked scrutiny and unsustainability; (4) AstraZeneca had reduced its financial commitments to Tempus through a questionable 'pass-through payment' via a joint agreement between it, the Company and Pathos AI; and (5) the foregoing issues revealed weakness in core operations and revenue prospects. The complaint alleges that on May 28, 2025, Spruce Point Capital Management, LLC issued a report on Tempus that raised numerous red flags over Tempus' management, operations and financial reporting. The Spruce Point Report scrutinized Tempus on an array of issues, including: (1) defendant Eric Lefkofsky and his associates have a history cashing out of companies before public shareholders incur losses or lackluster returns; (2) Tempus' actual AI capabilities are overstated; (3) board members and other executives have been associated with troubled companies that restated financial results; (4) signs of aggressive accounting and financial reporting; (4) issues with the AstraZeneca and Pathos AI deal that merit scrutiny; and (5) the Company's recent financial guidance reveals weakness in core operations. On this news, the price of Tempus common stock fell $12.67 per share, or 19.23%, from a closing price of $65.87 per share on May 27, 2025, to a closing price of $53.20 per share on May 28, 2025. What Now: You may be eligible to participate in the class action against Tempus AI, Inc. Shareholders who want to serve as lead plaintiff for the class should contact the firm. The lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here . All representation is on a contingency fee basis. Shareholders pay no fees or expenses. About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against Tempus AI, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today. Attorney Advertising. Past results do not guarantee a similar outcome.
Associated Press
14-06-2025
- Business
- Associated Press
VSTS Investor Notice: Robbins LLP Reminds Investors of the Class Action Lawsuit Against Vestis Corporation
SAN DIEGO, June 13, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Vestis Corporation (NYSE:VSTS) securities between May 2, 2024 and May 6, 2025. Vestis is a North American company that provides uniform rentals and workplace supplies across the U.S. and Canada. For more information, submit a form , email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Allegations that Vestis Corporation (VSTS) Misled Investors regarding Customer Growth According to the complaint, defendants failed to disclose to investors that Vestis would be unable to execute on planned strategic initiatives to drive purported improvements to the customer experience and its onboarding efforts in order to drive new customer growth, increased customer retention, and increased revenue from existing customers. The complaint alleges that these statements caused stockholders to purchase Vestis' securities at artificially inflated prices. According to the complaint, on May 7, 2025, Vestis announced its financial results for the second quarter of fiscal 2025, withdrew its revenue and growth guidance for the full fiscal year 2025, and provided guidance for the third quarter of fiscal 2025 that fell significantly below market expectations. The Company attributed its poor results partially to 'lost business in excess of new business,' but primarily on 'lower adds over stops, which is how we describe volume changes with our existing customers.' The Company attributed its decision to pull full-year guidance and provide disappointing third quarter targets to the 'increasingly uncertain macro environment.' On this news, the price of Vestis' common stock fell from a closing market price of $8.71 per share on May 6, 2025, to $5.44 per share on May 7, 2025, a decline of about 37.54% in the span of just a single day. What Now: You may be eligible to participate in the class action against Vestis Corporation. Shareholders who want to serve as lead plaintiff for the class must file a motion for lead plaintiff by August 8, 2025. The lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here . All representation is on a contingency fee basis. Shareholders pay no fees or expenses. About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against Vestis Corporation settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today. Attorney Advertising. Past results do not guarantee a similar outcome.
Associated Press
07-06-2025
- Business
- Associated Press
FTRE Investor Notice: Stockholder Rights Law Firm Robbins LLP Reminds Shareholders of the Class Action Against Fortrea Holdings, Inc.
SAN DIEGO, June 06, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Fortrea Holdings, Inc. (NASDAQ: FTRE) securities between July 3, 2023 and February 28, 2025. Fortrea is a global contract research organization ('CRO') that provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Allegations that Fortrea Holdings, Inc. (FTRE) Misled Investors Regarding the Progress of its Pre-Spin Projects The complaint alleges that Fortrea was formerly the clinical development and commercialization services business of Labcorp Holdings Inc., a life sciences and healthcare company. In June 2023, Labcorp spun off Fortrea as a standalone, publicly traded company. In connection with the Spin-Off, Labcorp and Fortrea entered into several transition services agreements (the 'TSAs'), pursuant to which Fortrea pays Labcorp to provide certain transitional services for a set period, including information technology applications, network and security support and hosting, as well as finance, human resources, marketing, and other administrative support. On March 3, 2025, Fortrea announced its fourth quarter and full year 2024 financial results, disclosing that its 'targeted revenue and adjusted EBITDA trajectories for 2025 [were] not in line with [its] prior expectations.' Specifically, in an earnings call held that same day, Fortrea revealed that the Company's Pre-Spin projects are 'late in their life cycle [and] have less revenue and less profitability than expected for 2025' and that 'post-spin work is not coming on fast enough to offset the pre-spin contract economics.' The Company also said this 'older versus newer mix issue will continue to negatively impact [Fortrea's] financial performance during 2025.' On this news, Fortrea's stock price fell $3.47 per share, or 25.05%, to close at $10.38 per share on March 3, 2025. According to the complaint, during the class period, defendants failed to disclose that: (i) Fortrea overestimated the amount of revenue the Pre-Spin Projects were likely to contribute to the Company's 2025 earnings; (ii) Fortrea overstated the cost savings it would likely achieve by exiting the TSAs; (iii) as a result, the Company's previously announced EBITDA targets for 2025 were inflated; and (iv) accordingly, the viability of the Company's post-Spin-Off business model, as well as its business and/or financial prospects, were overstated. What Now: You may be eligible to participate in the class action against Fortrea Holdings, Inc. Shareholders who want to serve as lead plaintiff for the class must file their motion with the court by August 1, 2025. The lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here. All representation is on a contingency fee basis. Shareholders pay no fees or expenses. About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against Fortrea Holdings, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today. Attorney Advertising. Past results do not guarantee a similar outcome. A photo accompanying this announcement is available at
